Organigram Global Inc. (OGI) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, my name is Tiffany and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Organigram Global fourth quarter fiscal 2025 earnings conference call. After the speaker's prepared remarks, there will be a Q&A session. Please limit yourself to one question and one follow up. You may requeue for additional questions. Thank you. I'll now turn the call over to Max Schwartz, Director of Investor Relations. Thank you, Tiffany. Good morning and thank you very much for joining us today. As a reminder, this call is being recorded and a replay will be available on our website within 24 hours. Today's call will include forward-looking statements. Actual results could differ material due to a number of risk factors outlined in our filings and the cautionary statements included in our Q4 fiscal 2025 press release and MD&A. We'll also reference certain non-IFRS measures, such as adjusted EBITDA, adjusted gross margin, and free cash flow. Definitions and reconciliations are available in our disclosure material. Unless otherwise noted, market share data is sourced from high-fire, weed crawler, provincial boards, retailers, and our own internal sales tracking. Discussing results today are Tim Enberg, President of Organigram Canada, and Greg Guyot, Chief Financial Officer. And we're also joined by our Executive Chair, Peter Amiro, for closing remarks. As a reminder, investor inquiries not addressed on today's call can be directed to investors at Organigram.ca. With that, I'll now turn the call over to Tim. Thanks, Max, and good morning, everyone. We are really excited to share our Q4 and full fiscal year 25 results with you. Fiscal 25 was a busy and redefining year for Organigram. We strengthened our Canadian market share leadership, achi...